1999. TRASPLANTAMENTS. PROJECTES FINANÇATS

Dr  José Francisco Aramburu Beltrán

J. Minguillón Pedreño, B. Morancho Armisen and J. Aramburu. . Immunosuppression and TGFb1: can we have one without fue other? Inmunología. 21: 134-144. 2002

Minguillón J., Morancho B., Kim SJ., López-Botet M., Aramburu J. Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-b1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-b1. J Leukoc. Biol. Vol 77  748-758, 2005,..

López-Rodríguez C., Aramburu J., Jin L., Rakeman AS., Michino M., Rao A. Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity. 15:47-58, 2001.

Dr  Manel Ballester Rodés

Dr  Joan X. Comella Carnicé

Dr  Ignasi Carrió Gasset

Dr  Joan Castell Conesa

Sanchis D., Mayorga M., Ballester M., Comella JX. Lack of Apaf-1 expression confers resistance to cytochrome c-driven apoptosis in cardiomyocytes. Cell Death and Differentiation (2003) 10, 977-986.

Mayorga M., Bahi N., Ballester M., Comella JX., Sanchis D. Bcl-2 Is a Key Factor for Cardiac Fibroblast Resistance to Programmed Cell Death. The Journal of Biological Chemestry, Vol. 279, No. 33, lBBue of August 13, pp. 34882-34889, 2004.  

Bahi N., Ballester. M., Comella. JX., Sanchis. D. Cardiac cell death during ischemia is caspase-independent and relies on AIF and EndoG activity. 2005 (in preparation).

Puig M., Ballester M., Matías-Guiu, Bordes R., Carrió I., Aymat MR., Marrugat J., Padró JM., Caralps JM., Narula J. Apoptosis of myocytes in cardiac allograft rejection. An additional mechanism of myocardial damage away from foci of myocyte necrosis. Circulation. J Nucl Cardiol 2000; 7: 132-9.

Simó M., Carrió I., Flotats A., Castell J., Campreciós M. et al. Characteristic Patterns of Myocardial Blood Flow and Metabolism after Heart Transplantation: Clinical and Prognostic Implications. Journal of the American College of Cardiology 2005 (submitted).

Simó M., Garcia JR., Soler M., Campreciós M., Lomena F., Carrió I. Enhanced FDG uptake after heart transplantation, relatioship with coronary blood flow, flow reserve and endomyocardial biopsy. Eur J Nucl. Med. 2004; 31: S323.

Simó M., García JR., Soler M., Flotats A., Campreciós M., Castell J., Pérez G., López S., Lomeña F., Carrió I. Estudio del flujo coronario basal, de la reserva miocárdica y del metabolismo cardíaco con tomografía de emisión de positrones. Rev. Esp. Med. Nucl. 2004; 23: 15.

Bayascas J.R., Yuste V.J., Sole C., Sanchez-Lopez I., Segura M.F., Perera R., Comella J.X. Characterization of splice variants of human caspase-activated DNase with CIDE-N structure and function. FEBS Lett. 2004 May 21;566(1-3):234-40.

Mayorga M., Bahi N., Ballester M.,  Sanchis D., Comella J.X. Bcl-2 is a key factor for cardiac fibroblast resistance to programmed cell death. J Biol Chem. 2004 Aug 13;279(33):34882-9. Epub 2004 Jun 7.

Benito-Gutierrez E., Nake C., Llovera M., Garcia-Fernandez J., Comella J.X. The single AmphiTrk receptor highlights increased complexity of neurotrophin signalling in vertebrates and suggests an early role in developing sensory neuroepidermal cells. Development. 2005 May;132(9):2191-202. Epub 2005 Mar 30.

Benito-Gutierrez E., Illas M., Garcia-Fernandez J., Comella J.X. Outlining the nascent nervous system of Branchiostoma floridae (amphioxus) by the pan-neural marker AmphiElav. Brain Res Bull. 2005 Sep 15;66(4-6):518-21. Epub 2005 Apr 2.

Dolcet X., Llobet D., Encinas M., Pallares J., Cabero A., Schoenenberger J.A., Matias-Guiu X., Comella J.X. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem. 2006 Aug 4;281(31):22118-30. Epub 2006 May 30.

Bahi N., Zhang J., Llovera M., Ballester M.,  Sanchis D., Comella J.X. Switch from caspase-dependent to caspase-independent death during heart development: essential role of endonuclease G in ischemia-induced DNA processing of differentiated cardiomyocytes. J Biol Chem. 2006 Aug 11;281(32):22943-52. Epub 2006 Jun 5.

Dr  Jordi Barquinero Máñez

Bueren JA., Segovia JC., Ramírez M., Güenechea G., Limón A., Barquinero J. Avances en la terapia génica de células madre hematopoyéticas. Methods Find Exp Clin Pharmacol 2001; 23 (SupI1): 5-7.

Cancelas JA., Querol S., Limón A., Amat LI., Barquinero J. Las células mesenquimales y su papel en la regulación de la hematopoyesis. Methods Find Exp Clin Pharmacol 2001; 23 (SupI1): 21-4.

Puig T., Kádár E., Limón A., Cancelas JA., Eixarch H., Luquín L., García M., Barquinero J. Myeloablatíon enhances engraftment of transduced muríne hematopoíetíc cells but does not ínfluence long-term expressíon ofthe transgene. Gene Therapy 2002; 9: 1472-1479.

Barquinero J., García M. Terapia génica para enfermedades hereditarias: realidad o ficción. Med Clin 2001; 117: 778-780.

Barquinero J., Eixarch H., Pérez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther 2004; 11: S3-9 .

García-Escarp M., Martínez-Muñoz V., Barquinero J., Marín P., Pétriz. J. A flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of mitoxantrone. Cytometry, 2004; 62A: 129-138.

Pétriz J., Roig-Camach. J., Barquinero. J., Marín. P. Human hematopoietic CD34+ cells greatly differ in telomere length. Cell Tiss Res, 2005; 319: 405-412.

Barquinero J., Pellicer M., Pétriz J. Aplicaciones terapéuticas de las células madre. Med Clin Barcelona, 2005; 124: 504-511.

Ramon y Cajal S., Barquinero J., Alemany R. Terapia génica: realidades actuales y expectativas. Rev Clin Esp, 2005; 205: 178-188.

Eixarch H., Espejo C., Vidal F., Garcés S., Castillo M., Bote A., Kádár E., Rosal M., Montalbán X., Barquinero J. Molecular chimerism prevents Experimental Autoimmune Encephalomyelitis (EAE). 8th Annual Meeting of the American Society of Gene Therapy, St Louis (EEUU), 2005. Molecular Therapy 2005; 11: S167 (supl 1).

Dr  Lluís Blanch Torra

López-Aguilar J., Villagrá A., Bernabé F., Murias G., Piacentini E., Real J., Fernández-Segoviano P., Romero MD PV., Hotchkiss JR., Blanch. Ll. Massive brain injury enhances lung damage in an isolated lung model of ventilator-induced lung injury. Crit Care Med 2005, 33:1077-1083 .

López-Aguilar J., Piacentini E., Villagrá A., Murias G., Pascotto S., Saenz-Valiente A., Fernández-Segoviano P., Hotchkiss JR., Blanch Ll. Contributions of vascular flow and pulmonary capillary pressure to ventilator-induced lung injury. Crit Care Med 2006 34 (4) :1106-12.

Saenz-Valiente A., Piacentini E., Villagrá A., Lopez-Aguilar J., Murias G., Blanch Ll. Papel de la microcirculación en el desarrollo de la lesión pulmonar aguda inducida por la ventilación mecánica. Medicina Intensiva 2005; 29:226-235.

Ventrice E.A., Martí-Sistac O. , Gonzalvo R., Villagrá A. , López-Aguilar  J.,    Blanch L.. Mecanismos biofísicos, celulares y modulación de la lesión pulmonar inducida por la ventilación mecánica.  Med Intensiva. 2007;31(2):73-82

Dr  Francisco Blanco Vaca

Escola-Gil JC., Arcelus R., Julve J., Zapico É., Blanco Vaca F. Evaluación de un modelo animal para el estudio de la interacción hiperhomocisteinemia-diabetes y su efecto en la arteriosclerosis. Clínica e Investigación en Arteriosclerosis 2002; 14 (supl 2). 63.

Blanco-Vaca F., López N., Cuquet J., Mateo J. Patient presenting multiple venous and arterial atherothrombotic events despite intensive treatment: evolution and clinical response after normalization of plasma homocysteine. Journal of Internal Medicine (in preparation).

Souto JC., Blanco-Vaca F., Soria JM., Buil A., Ordóñez-Llanos J., Lathrop M., Almasy L.,  Stone W., Blangero J., Fontcuberta J. A quantitative trait locus on chromosome 11 is a major determinant of plasma homocysteine levels: implications for cardiovascular and late-onset Alzheimer's disease. New England Journal of Medicine (in preparation).

lanco-Vaca F., López N., Cuquet J., Mateo J. Patient presenting multiple consecutive venous and arterial thrombotic events despite intensive conventional treatment: response after normalization of plasma homocysteine and N-acetylcisteine therapy. J Intern Med. 2003 Oct; 254 (4): 397-400

Calpe-Berdiel L., Escolà-Gil JC., Ribas V., Arcelus R., Blanco Vaca F. Caracterización de un modelo murino en el que la deficiencia parcial de folato no induce hiperhomocisteinemia. Clínica e Investigación en Arteriosclerosis 2004; 16 (5): 192

Dr  Mercè Brunet Serra

Brunet M., Millán O., Jiménez O. et al. New Concepts in Cyclosporine Pharmacokinetic and Dynamic Monitoring: The Impact of Concomitant Immunosuppression on Target C2 Concentrations. Transplantation Proceedings, March 2004, 36: Issue 2, S1:S437-S441.

Brunet M., Campistol JM., Millán O. et al. Pharmacokinetic and Pharmacodynamic correlations of Cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C2. International Immunopharmacology 2003; 3:987-999. 

Brunet M., Millán O., Martorell J. et al. Six month PKs/PDs relationship evolution in renal transplant treated with calcineurin inhibitors and Mycophenolate Mofetil: the role of IL-2, IFN-?, calcineurin activity and T cell proliferation (submitted).

Dr  Antoni Camins Espuny

Canudas AM., Jorda EG., Verdaguer E., Jimenez A., Sureda FX., Rimbau V., Camins A., Pallas M. Cyclosporin A enhances colchicine-induced apoptosis in rat cerebellar granule neurons. British Journal of Pharmacology 141:661-669 (2004).

Dr  Josep M. Campistol Plana 

Crespo M., Campistol JM. Disfunción endotelial en el trasplante Renal. Nefrologia, 2003; 23 Suppl 4:52-8.

Campistol JM. Las arterias de resistencia mesentérica de ratas cirróticas son hipersensibles y constituyen una diana prefencial para la acción vasorelajante del cannabinoide endogeno anandamida. Gastroenterología y Hepatología, Vol.26, Supl.2, 67, 2003.

Domenicali M., Ros J., Fernandez-Varo G., Cejudo-Martin P., Crespo M., Morales M., Briones A., Campistol JM., Arroyo V., Vidal E., Rodes J., Jimenez W. Increased anandamide-induced relaxation in mesenteric arteries of cirrhotic rats. Role of cannabinoid and vanilloid receptors. Gut 2005, 54 (4): 522-7.

Dr  Elías Campo Güerri

Cibeira MT., Lopez-Guillermo A., Colomer D., Ricart MI., Alcaraz A., Martinez A., Campo E., Montserrat E. Diffuse large B-celllymphoma arising from donar Iymphoid cells after renal and pancreatic transplantation. Ann Rematol. 2003; 82:131-135.

Segarra M., Vilardell C., Esparza J., Perales M., Serra C., Yarnada KMt., Cid MC. Signal Transduction pathways involved in integrin-mediated MMP-2 arnd MMP-9 production by lymphocytes. Arthritis Rheum 2002; 46 (suppl): S34.

Segarra M,, Vilardell C,, Esparza J,, Perales M,, Serra C,, Yarnada KM,, Cid MC. Signal transduction pathways involved in integrin-mediated MMP-2 arnd MMP-9 production byT lymphocytes. Arthritis Rheum 2002; 46 (suppl): S78.

Segarra M., Lozano E., Vilardell C., Esparza J., Izco N., Bladé J., Campo E., Cid MC.. Thalidomide decreases fibronectin-induced MMP-2 and MMP-2 production by B lymphoid cell lines. FASEB J 2004; 18: A68 

Segarra M., Vilardell C., Esparza J., Lozano E., Serra C., Campo E., Yamada KM., Cid MC. Dual role of focal adhesion kinase in regulating fibronectin-induced gelatinase (MMP-0 and MMP2) production and release by T lymphoid cell lines. FASEB J 2004; 18: A1114 

Colomo L., Loong F., Rives S., Pittaluga S., Martinez A., Lopez-Guillermo A., Ojanguren J., Romagosa V., Jaffe ES., Campo E. Diffuse large B-cell lymphoma with plasmablastic differentiation represent a heterogeneous group of disease entities. USCAP meeting Vancouver, March 2004. Lab Invest 2004 (suppl): A1027 

Segarra M., Vilardell C., Esparza J., Perales M., Serra C., Yamada KM., Cid MC. Signal Transduction pathways involved in integrin-mediated MMP-2 amd MMP-9 production by T lymphocytes. ACR Basic Research Conference New Orleans LA. October 2002. Arthritis Rheum 2002; 46 (suppl): S34).

Segarra M., Vilardell C., Esparza J., Perales M., Serra C., Yamada KM., Cid MC. Signal Transduction pathways involved in integrin-mediated MMP-2 amd MMP-9 production by T lymphocytes. 66th ACR Annual Scientific Meeting. New Orleans LA. October 2002. Arthritis Rheum 2002; 46 (suppl): S78.

Colomo L., Long F., Rives S., Pittaluga S., Martinez A., Lopez-Guillermo A., Ojanguren J., Romagosa V., Jaffe ES., Campo E. Diffuse large B-cell lymphoma with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004; 28:736-747.

Rosiñol L., Cibeira MT., Segarra M., Cid MC., Filella X., Aymerich M., Rozman M., Arenillas L., Esteve J., Bladé J., Montserrat E. Response to thalidomide in múltiple myeloma: impact of angiogenic factors. Cytokine 2004; 26: 145-148.

Segarra M., Vilardell C., Matsumoto K., Esparza J., Lozano E., Serra-Pages C., Urbano-Márquez A., Yamada KM., Cid MC. Dual function of focal adhesión kinase in regulating integrin-mediated MMP-2 and MMP-9 release by human T lymphoid cell lines. FASEB J; 2005 : Vol 19, 1875-1877

Segarra M., Lozano E., Vilardell C., Esparza J., Izco N., Bladé J., Campo E., Cid MC. Thalidomide decreases fibronectin -induced gelatinase (MMP-2 and MMP-9) production by malignant B lymphoid cell lines (in preparation)

Dr  Teresa Casanovas Taltavull

Casanovas Taltavull T. Adaptación transcultural del cuestionario específico de calidad de vida para hepatopatiascrónicas (LDQOL 1.0) para su uso en población española. Gastroenterol Hepatol 2003; 26:234-244.

Casanovas T. Adaptació transcultural del qüestionari especific de qualitat de vida per hepatopatíes cróniques (LDQOL 1.0) a la població espanyola. Xl Congrés de la Societat Catalana de Digestologia (Reus, 31 de gener 2002). Gastroenterol Hepatol 2002; 25 (2):113-141. 

Casanovas T. Adaptació transcultural del qüestionari especific de qualitat de vida per hepatopatíes cróniques (LDQOL 1.0) a la població espanyola. XXVll Congreso Nacional de la Asociación Española para el Estudio del Hígado. Gastroenterol Hepatol 2002; 25 (Supl. 1):55-116.

Casanovas T. Adaptació transcultural del qüestionari especific de qualitat de vida per hepatopatíes cróniques (LDQOL 1.0) a la població espanyola. Revista Bellvitge Informatiu Desembre de 2002 (pag. 4-6) 

Casanovas T., Vallejo G., Herdman M., Casado A., Ribas S., Tremosa G., Rodríguez Fariña E. et al. Validation of the Spanish version of the Liver Disease Quality of Life Questionnaire in Transplant patients. Transpl. Proceed 2003; 35: 1803-1805.

Casanovas T. Capítol "Calidad de vida después del Trasplante Hepático" Trasplante de órganos sólidos. Ed. Drug-Pharma. Madrid 2004

Dr  Antonio Celada Cotarelo

Comalada M., Valledor A.F., Umbert l., Xaus J. y Celada A.: M-CSF-dependent macrophage proliferation is mediated through a calcineurin- independent but immunophilin-dependent mechanism that mediates the activation of External Regulated Kinases. European Journal of Immunology 33: 3091-3100, 2003 

Brucet M., Marqués L., Sebastian C., Lloberas J. i Celada A. Regulation of murine TAP1 and LMP2 genes in macrophages by interferon gamma is mediated by Stat1 and IRF-1. Genes and Immunity 5: 26-35, 2004 

Marqués L., Brucet M., Lloberas J. i Celada A. STAT1 regulates lipopolysaccharide- and TNF-?-dependent expression of Transporter Associated with Antigen Processing 1 and Low Molecular Mass Polypeptide 2 genes in macrophages by different mechanisms. Journal of Immunology 173: 1103-1110, 2004 

Casals C., Barrachina M., Serra M, Lloberas J. i Celada A. LPS upregulates MHC Class II expression on dendritic cells and B lymphocytes through a conserved AP-1 sequence without increasing CIITA (submitted).

Lloberas J., Serrat N., Barrachina M. i Celada A. The transcription of the MHC class II genes requires that CIITA opens the locus control region (submitted).

Casals C., Barrachina M., Serra M, Lloberas J. y Celada A. : LPS  upregulates MHC Class II expression on dendritic cells through an AP-1  enhancer without affecting the levels of CIITA. Journal of Immunology 178: 6307-6315, 2007

Dr  Àngel Ramon Cequier Fillat

Lopez S., Gomez-Hospital JA., Cequier A., et al. Disfunción endotelial inicial como factor predictivo de enfermedad vascular del injerto y mortalidad tardía en trasplantados cardiacos. Congreso de las Enfermedades Cardiovasculares. Sevilla, 15-18 octubre, 2003. Rev. Esp. Cardiol 2003; supl 2: 155. 

Iraculis E., Gómez-Hospital JA., Cequier A., et al. La disfunción endotelial inicial en el trasplante cardiaco no se correlaciona con la aterosclerosis coronaria del donante estudiada mediante ecocardiografia intracoronaria. Congreso de las Enfermedades Cardiovasculares. Sevilla, 15-18 octubre, 2003. Rev. Esp. Cardiol 2003; supl 2: 173.

López S., Iràculis E., Gómez-Hospital JA., Cequier A., et al. Alta prevalencia de aterosclerosis coronaria en jóvenes asintomáticos. Implicaciones mediante un estudio de ecografia intracoronaria en donantes cardiacos. Congreso de las Enfermedades Cardiovasculares. Sevilla, 15-18 octubre, 2003. Rev. Esp. Cardiol 2003; supl 2: 111.

Lopez S., Gomez-Hospital JA., Cequier A., et al. Early endothelial dysfunction is a predictive factor of mortality at follow-up after heart transplantation. European Society of Cardiology Congress 2004. Eur Heart J. 2004; 25 (suppl): 580. 

Lopez S., Gomez-Hospital JA., Cequier A., et al. Early endothelial dysfunction is a predictive factor of development of coronary allograft vasculopathy after heart transplantation. European Society of Cardiology Congress 2004. Eur Heart J. 2004; 25 (suppl): 576-577. 

Lopez S., Gomez-Hospital JA., Manito N., Cequier A., et al. Disfuncion endotelial inicial y enfermedad vascular del injerto en trasplantados cardiacos. Congreso de Enfermedades Cardiovasculares. Madrid, 20-23 octubre, 2004. Rev. Esp. Cardiol 2004; 57 (supl 2): 42.

Lopez S., Iraculis E., Gomez-Hospital JA., Manito N., Cequier A. La disfunció endotelial inicial en el trasplantament cardiac no es correlaciona amb l'aterosclerosi coronaria del donant estudiada mitjançant ecografia intracoronaria. Rev. Soc. Cardiol 2004; 5 (supl 3): 30.

Lopez S., Iraculis E., Gómez-Hospital JA., Cequier A. Disfunció endotelial inicial com factor predictiu de malaltia vascular de l'empelt en trasplantats cardiacs. Rev. Soc. Cardiol 2004; 5 (supl 3): 77.

Lopez S., Iraculis E., Gómez-Hospital JA., Cequier A. Disfunció endotelial inicial predictiu de mortalitat tardana en trasplantats cardiacs. Rev. Soc. Cardiol 2004; 5 (supl 3): 79.

Dr  Pablo Engel Rocamora

Romero X., Benitez D., March S., Vilella R., Miralpeix M., Engel P. Differential expression of SAP and EAT-2 -binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens 2004 64:132-144.

Romero X., Zapater N., Calvo M., Kalko SG., De la Fuente, Tovar V., Ockeloen C., Pizcueta P., Engel P. CD229 (Ly9) lymphocyte cell-surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol 2005 174:7033-7042.

Saborit I., Del Valle J., Romero X., Esplugues E., Lauzurica P., Engel P., Martin M. The adaptor protein 3BP2 binds to human CD244 and links this receptor to Vav signaling, ERK activation and NK killer. J Immunol 2005 (in revision).

Dr  Carlos Enrich Bastus

Tebar F., Villalonga P., Sorkina T., Agell N., Sorkin A., Enrich C. Calmodulin regulates intracellular trafficking of epidermal growth factor receptor and the MAPK signaling pathway. Molecular Biology of the Cell (2002) 13, 2057-2068. 

Tebar F., Lladó A., Enrich C. Calmodulin interferes the transactivation of epidermal growth factor receptor mediated by PKC. Febs Letters (2002) 517, 206-210. 

Pol A., Martin S., Fernández MA., Ferguson C., Carozzi A., Luetterforst R., Enrich C., Parton RG. Dynamic and regulated association of caveolin with lipid bodies: modulation of lipid body motility and function by a dominant negative mutant. Molecular Biology of the Cell (2004) 15, 99-110.

Fernández MA., Turró S., Ingelmo-Torres M. Enrich, C., Pol A. Intracellular trafficking during liver regeneration. Alterations in late endocytic and transcytotic pathways. Journal of Hepathology (2004) 40, 132-139. 

Pol A., Martin S., Fernández MA., Ingelmo-Torres M., Ferguson C., Enrich C., Parton RG. Cholesterol and fatty acids regulate dynamic caveolin trafficking through the Golgi complex and between the cell surface and lipid bodies. Molecular Biology of the Cell (2005) 16, 2091-2105. 

Fernandez MA, Turró S., Ingelmo-Torres M., Grewal T., Enrich C., Pol A. Regulated association of caveolin with fatty acid-induced lipid bodies but not with lipid bodies formed in response to glucose/insulin. Traffic (2005) (re-submitted).

Dr  Joan Ignasi Esteban Mur

Quer J., Murillo P., Esteban JI., Martell M., Esteban R,. Guardia J. Sexual transmission of hepatitis C virus from a patient with chronic disease to his sex partner after removal of an intrauterine device. Sex Transm Dis. 2003 May; 30 (5):470-471. 

Quer J., Murillo P., Martell M., Gomez J., Esteban JI., Esteban R., Guardia J. Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. J Viral Hepat. 2004 Jan; 11 (1):45-54.

Cos J., Ocaña L., Quer J., Bilbao I., Esteban JI., Borràs FE., Tejeda M., Guardia J., Massuet Ll., Margarit C. FK506 down-regulated maturation of dendritic cells pulsed with a nonstructural protein (NS3) of hepatitis C virus. 2005 Haematologica (submitted).

Quer J., Murillo P., Cos J., Esteban JI., Esteban R., Guàrdia J. Improved attachment of natural HCV isolate to Daudi cells upon elimination of immune complexes and close pH control. Intervirology 2005; 48(5): 285-291.

Quer J., Cos J., Sauleda S., Ocaña L., Murillo P., Otero T., Esteban JI., Esteban R., Guàrdia J. Evolution of the gene encoding the complete nonstructural 3 protein (ns3) of hepatitis c virus (hcv) during chronic infection and after transmission to a new host. J.Virol (in preparation).

Quer, J; Esteban, JI; Cos, J; Sauleda S; Ocaña L; Martell M; Otero T; Cubero M; Palou E; Murillo, P;; Esteban, R; Guardia, J. Effect of bottlenecking on evolution of the nonstructural protein 3(NS3) gene of hepatitis C virus during sexually-transmitted acute resolving infection. Journal of Virology Dec.2005;79(24):15131-15141

Dr  Elvira Dolores Fernández Giráldez

Cardús A., Parisi E., Gallego C., Aldea M., Fernández E., Valdivielso JM. 1,25-Dihydroxyvitamin D3 Stimulates Vascular Smooth Muscle Cell Proliferation Through a Vegf-mediated Pathway. Journal of the American Society of Nephrology (in revision).

Cardus A., Gallego C., Muray S., Marco MP., Parisi E., Aldea M., Fernandez E. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia. 2003; 23 Suppl 2:117-21.

Dr  Patricia Fernández-Llama

Ageloff S, Fernández-Llama P, Fernández-Varo G, Ros J, Garra N, Ballarin J, Arroyo V, Stokes JB, Knepper MA, Jiménez W. Proteomic Analysis of Renal Sodium Transporters and Channels in the Kidney of Cirrhotic Rats with Ascites (in preparation)

Fernández-Llama P., Ageloff S., Fernández-Varo G., Ros J., Wang X., Garra N., Esteva C., Ballarin J., Barcelo P., Arroyo V., Stokes JB., Knepper MA., Jiménez W. Sodium Retention in Cirrhotic Rats is Associated with Increased Renal Abundances of Sodium Transporter Proteins. Kidney Int 67, 662-630, 2005.

Esteva-Font C., Ars E.,  Guillen E.,  Campistol J.M., Sanz L.,  Jiménez W., Knepper  M.A.,  Torres F., Ballarín J.A., Fernández-Llama P.   Cyclosporine-induced Hypertension is Associated with Increased Sodium Transporter of the Loop of Henle (NKCC2)  Nephrol Dial Transplant (2007 ) doi:10.1093/ndt/gfm390

Dr  Xavier Forns Bernhardt

Feliu A., Forns X., Gay E., Sáiz JC., Rodés J. Genetic evoluction of hepatitis C virus (HCV) after liver transplantation (LT). Congrès Anual de la Societat Europea d'Hepatologia (EASL). Madrid febrer 2002. J Hepatol 2002; 36:37

García-Retortillo M., Forns X., Serrano T., F. Suárez, de la Mata M., Navasa M., García-Valdecasas JC, Rimola A., Rodés J. Safety and efficacy of combined treatment with interferon and ribavirin in HCV-infected patients awaiting liver transplantation. 53th Annual Liver Meeting de la AASLD . Boston , Massachussets Novembre 2002. Hepatology 2002; 36(4):177A. 

García-Retortillo M., Forns X, Serrano T, Suárez F., de la Mata M., Navasa M., García-Valdecasas JC, Rimola A., Rodés J. Safety and efficacy of combined treatment with interferon and ribavirin in HCV-infected patients awaiting liver transplantation. 9th Meeting of the International Liver Transplantation Society (ILTS). Barcelona, Juny de 2003. Liver Transpl 2003; 9(6): C-34.

Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M., Rimola A., Rodes J. Hepatitis C virus (HCV) kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687 

Forns X., García-Retortillo M., Serrano T., Feliu A., Suárez F., de la Mata M., García-Valdecasas JC., Navasa M., Rimola A., Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-396.

Dr  Josep Fuster Obregon

García-Valdecasas JC., Fuster J., Charco R., Bombuy E., Fondevila C., Ferrer J., Ayuso C., Taura P. Changes in portal flow after adult living-donor liver transplantation: does it influence postoperative liver function?. Liver Transplantation 2003 Jun; 9(6) : 564-9. 

García-Valdecasas JC., Fuster J., Charco R., Bombuy E., Fondevila C., Ferrer J., Ayuso C., Rodriguez-Laiz G., Amador MA, Taura P. Trasplante hepàtica de donante vivo en adultos. ¿Pueden influir los cambios del flujo portal en la función hepàtica postoperatoria?. Cirugía Española. 2003; 74:340-6. Premi Nacional de Cirugía 2003 de la Asociación Española de Cirujanos.

Dr  David Gallardo Giralt

Pujal JM., Grinyó JM., Manito N., Gil-Vernet S., Hueso M., Caldés A., Costa S., Benéitez D., Grañena A., Gallardo D. Influence of hematopoietic microchimerism in organ tolerance after kidrtey or heart transplantation. Transplant Frac. 2003 Aug; 35 (5) :1775-1777.

Pujal JM., Gallardo D., Costa S., Beneitez D., Grañena A. Influencia del microquimerismo hematopoyético en la tolerancia del órgano en trasplante renal y cardíaco. Haematologica 2002; 87 (suppl 2): 22.

Dr  Juan-Carlos García-Valdecasas Salgado

Net M, Valero R, Almenara R, Deulofeu R, Lopez-Boado MA, Capdevila L, Barros P, Bombi JA, Agustí M, Adalia R, Ruiz A, Arce Y, Manyalich M, García- Valdecasas JC. Hepatic preconditioning alter prolonged warm ischemia by means of S-adenosyI-L-methionine administration in pig. Trasplantation, 2003 Jun 27; 75 (12): 1970-7

Valero R., García-Valdecasas JC., Net M., Beltran J., Ordi J., González FX., López-Boado MA., Almenara R., Taurá P., Elena M., Capdevila L., Manyalich M., Visa J. L-arginine reduces liver and biliary tract damage after liver transplantation from non-heart-beating donor pigs. Transplantation 2000; 70:730-37

Net M., Valero R., Almenara R., Rull R., Gonzalez FX., Taurá P., López-Boado MA., Deulofeu R., Elena M., Capdevila LL., Cabrer C., Visa J., Valdecasas JC. Hepatic xanthine levels as viability predictor of livers procured from non-heart-beating donors pigs. Transplantation 2001; 71:1232-1237

Net M., Barros P. Reduced reperfusion injury by glycine in a porcine liver transplantation model with non-heart beating donors. Transplantation Proceedings, Volume 34, Issue 4, June 2002, Page 1114

Net M., Valero R., Almenara A. The effect of normothermic recirculation is mediated by ischemic preconditioning in NHBD liver transplantation. American Journal of Transplantation 2005 (in press)

Dr  Miquel Àngel Gassull Duro

Dr  Kimberlay M. Olthoff

Dr  Ester Fernández Gimeno

Río A., Fernández E., Aldeguer X. Gassull MA. IL6 independet STAT3 activation in a murine model of hepatic fibrosis (in preparation).

Río A., Fernández E., Aldeguer X., Llor, X., Gassull MA. Activación IL6 independiente de STAT3 en un modelo murino de fibrosis hepática. VII Congreso de la Asociación Española de Gastroenterología. Madrid 25-27 de març de 2004. Gastroenterología y Hepatología 2004; 27(3):177-234.

Río A.,  Gassull M.A., Aldeguer X.,  Ojanguren I., Cabré E., Fernández E. Decreased injury in interkeukin-6 knockout mice after CCl4- induced liver damage European Journal of Clinical Investigation (2007 editorial review)

Dr  Gabriel Gil Gómez

Granés F., Roig M.B., Brady H JM., Gil-Gomez G. Cdk2 activation acts upstream of the mitochondrion during glucocorticoid induced thymocyte apoptosis. Eur. J. Immunol. 2004. 34:2781-2790.

Dr  Pere Ginés Gibert

Ortega R., Gines P., Uriz J., Cardenas A., Calahorra B., De Las Heras D., Guevara M., Bataller R., Jimenez W., Arroyo V., Rodes J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002; 36:941-8.

Restuccia T., Guevara M., Gines P., Alessandria C., Ozdogan O., Navasa M., Rimola A., García-Valdecasas JC., Arroyo V., Rodés J. Treatment of Hepatorenal Syndrome before transplantation. Effect on post-transplant outcome. A case-control study (pendent de publicar).

Restuccia T., Ortega R., Guevara M., Ginès P., Alessandria C., Ozdogan O., Navasa M., Rimola A., Garcia-Valdecasas JC., Arroyo V., Rodes J. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004; 40:140-6. 

Guevara M., Fernández-Esparrach G., Alessandria C., Torre A., Terra C., Montañà X., Piera C., Alvarez ML., Jiménez W., Ginès P., Arroyo V. Effects of contrast media on renal function in patients with cirrhosis: A prospective study. Hepatology 2004; 40:646-651.

Ginès P., Guevara M., Perez-Villa F. Management of hepatorenal syndrome: another piece of the puzzle. Hepatology. 2004; 40:16-8.6. 

Ginès P., Guevara M., Arroyo V., Rodes J. Hepatorenal syndrome. The Lancet. 2003 29; 1819-27.

Ginès P., Cardenas A., Arroyo V., Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004 15; 1646-54.

Ortega R., Ginès P., Uriz J., Calahorra B., Cardenas A., De las Heras D., Guevara M., Jiménez W., Arroyo V., Rodés J. Effects of terlipressin administration with and without albumin in hepatorenal síndrome (HRS). A phase II study. J Hepatol 2002; 36(S1)38A

Restuccia T., Guevara M., Ginès P., Alessandria C., De las Heras D., Calahorra B., Ortega R., Navasa M., Rimola A., Garcia-Valdecasas JC., Arroyo V., Rodés J. Impacto del tratamiento del Síndrome hepatorrenal (SHR) con análogos de la vasopresina antes del rasplante hepático sobre la evolución post-trasplante. Estudio caso-control. XII Congreso de la Societat Catalana de Digestologia. Gastroenterol Hepatol 2003; 26 (2): 127. 

Restuccia T., Guevara M., Ginès P., Alessandria C., De las Heras D., Calahorra B., Ortega R., Navasa M., Rimola A., Garcia-Valdecasas JC., Arroyo V., Rodés J. Impact of pretransplant treatment of hepatorenal síndrome (HRS) with vasopressin analogues on outcome after liver transplantation (LTX). A case-control study. EASL 2003. J Hepatol 2003; 38 (Suppl 2): 69.

Restuccia T., Guevara M., Ginès P., Alessandria C., De las Heras D., Calahorra B., Ortega R., Navasa M., Rimola A., Garcia-Valdecasas JC., Arroyo V., Rodés J. Impact of pretransplant treatment of hepatorenal síndrome (HRS) with vasopressin analogues on outcome after liver transplantation (LTX). A case-control study. Liver Transplantation 2003; 9:144.

Guevara M., Alessandria C., Ortega R., De las Heras D., Uriz J., Torre A., Terra C., Jiménez W., Ginès P., Arroyo V. Eficacia de la terlipresina en la prevención de la disfunción circulatoria post-paracentesis en pacientes con cirrosis y ascitis. Estudio en fase II. XIII Congreso de la Asoc. Catalana de Digestología. Gastroenterol Hepatol 2004; 27:82.

Guevara M., Alessandria C., Ortega R., De las Heras D., Uriz J., Torre A., Terra C., Jiménez W., Ginès P., Arroyo V. Eficacia de la terlipresina en la prevención de la disfunción circulatoria post-paracentesis en pacientes con cirrosis y ascitis. Estudio en fase II. XXIX Congreso de la Asociación Española para el estudio de las enfermedades del Hígado. Gastroenterol Hepatol 2004; 27 Supl.

Dr  Luis Grande Posa

Fernández L., Heredia N., Grande L., Gómez G., Rimola A., Marco A., Gelpí E., Roselló-Catafau J., Peralta C. Preconditioning protects the liver and lung damage in rat liver transplantation: Role of xanthine/xanthine oxidase. Hepatology 36: 562-572 (2002).

Fernández L., Heredia N., Peralta C., Roselló-Catafau J., Rimola A., Marco A., Serafín A., Deulofeu R., Gelpí E., Grande L. Role of ischemic preconditioning and portosystemic shunt in the prevention of liver and lung damage following rat liver transplantation. Transplantation 76: 282-289 (2003).

Dr  M. Magdalena Heras Fortuny

Solanes N., Rigol M., Castellà M., Khabiri E., Ramírez J., Segalés J., Roqué M., Agustí E., Pérez-Villa F., Roig E., Pomar JL., Sanz G., Heras M. Cryopreservation alters antigenicity of allografts in a porcine model of transplant vasculopathy. Transpl. Proceedings 2004; 36(10):3288-94.

Solanes N., Rigol M., Ramírez J., Segalés J., Roqué M., Marimon JM., Pérez-Villa F., Roig E. Histological Basis of the Porcine Femoral Artery for Vascular Research. Anat. Histol. Embryol. 2005; 34:105-111 .

Gálvez C., Rigol M., Solanes N., Sionis A., Brunet M., Ramírez J., Barquín L., Roqué M., Roig E., Pérez Villa F., Sanz G., Heras M. Efectes histològics del tractament amb rapamicina i ciclosporina en un model de trasplantament d'artèries femorals porcines. Rev. Societat Catalana Cardiologia 2004; 5 (3):64.

Solanes N., Rigol M., Gálvez C., Sionis A., Brunet M., Ramírez J., Barquín L., Roqué M., Roig E., Pérez Villa F., Sanz G., Heras M. El tractament amb rapamicina preveu les lesions histològiques a la capa mitjana d'empelts femorals porcins. Rev. Societat Catalana Cardiologia 2004. 5 (3):78.

Solanes N., Rigol M., Khabiri E., Castellà M., Ramírez J., Roqué M., Agustí E., Roig E., Pérez-Villa F., Segalés F., Pomar J.L., Engel P., Massaguer A., Martorell J., Rodríguez J.A., Sanz G., Heras M. Effects of cryopreservation on the immunogenicity of porcine arterial allografts in early stages of transplant vasculopathy. Cryobiology 2005;51(2)130-140.

Dr  Wladimiro Jiménez Povedano

M.Morales-Ruiz, P .Cejudo-Martín, G.Fernández-Varo, S. Tugues, J.Ros, P.Angeli, F.Rivera, V.Arroyo, J.Rodés, WC.Sessa, W.Jiménez. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003; 125:522-531.

V.Arroyo, P.Ginés, J.Rodés, R.W.Schrier M.Morales-Ruiz and W.Jiménez. Pathophysiological raje of nitric oxide in cirrhosis. Ascites and renal dysfunction in liver disease. Pathogenesis Diagnosis and Treatment eds. Blackwell Science Inc. Malden, Massachussets, USA. 2004 (in press).

M.Morales-Ruiz and W.Jiménez. Neovascularization, angiogenesis and vascular remodeling in portal hypertension. Portal Hypertension: Pathobiology, Evaluation, and Treatment. V.Shah and A.Sanyal eds. Humana Press (in press).

Morales-Ruiz M., Cejudo-Martín P., Tugues S., Ros J., Fernández-Llama P., Arroyo V., Rodés J., Jiménez W. Ascites from cirrhotic patients induces angiogenesis through the activation of the phosphoinositide 3-kinase/AKT signaling pathway. Journal of Hepatology  43 (2005) 85-91.

Morales-Ruiz M., Fondevila C.,  Muñoz-Luque J.,  Tugues S.,  Rodríguez Laiz G.,Cejudo-Martín  P., Romero J.M.,  Navasa  M.,  Fuster  J.,  Arroyo  V., Sessa W.C. ,  García-Valdecasas J. C. , Jiménez W. Gene Transduction of an Active Mutant of Akt Exerts Cytoprotection and Reduces Graft Injury After Liver Transplantation in pigs American Journal of  Transplantation 2007; 7: 769-778

Morales-Ruiz M.,  Jiménez W. Chapter 8 - Nitric oxide and systemic and renal hemodynamic disturbances in cirrhosis ch08.indd 105-114

Dr  Josep M. Llovet

Llovet JM,, Mas X., Aponte JJ., Fuster J., Navasa M., Christensen E., Rodés J., Bruix J . Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50:123-128

Sarasin F., Majno P., Llovet JM., Mentha J., Bruix J., Hadengue A. Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness persepctive. Hepatology 2001; 33:1073-1079 

Llovet JM., Beaugrand M. Hepatocellular carcinoma: Present status and future prospects. J Hepatol 2003; 38 Suppl 1:S136-49.

Llovet JM., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442. 

Llovet JM., Sarasin F., Majno P., Mentha J., Hadengue A., Bruix J. Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. 36th European Congress of EASL. Praga, 2001. Working party. J Hepatol 2001; 34 (Suppl 1): 8A.

Majno P., Sarasin F., Llovet JM., Bruix J., Mentha J., Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. ILTS-ELTA-LIGACE Berlin, 2001. Liver Transplantation 2001; 7:C-71A.

Llovet JM., Sarasin FP., Majno P., Mentha G., Hadengue A., Bruix J . Trasplante hepático de donante vivo para el carcinoma hepatocelular. Análisis de coste-efectividad. XXVI Congreso de la AEEH. Madrid, 2001. Gastroenterol y Hepatol 2001; 24:87A.

Dr  José Miguel López-Botet Arbona

Bellón T., Kitzig F., Sayós J., López-Botet M. Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. J Immunol. 168:3351-3359, 2002. 

García P., Llano M., de Heredia AB., Willberg CB., Caparrós E., Aparicio P., Braud VM.,  López-Botet M. Human T cell receptor- mediated recognition of HLA-E. Eur.J. Immunol. 32:936-944, 2002.

Llano M., Guma M., Ortega M., Angulo A., López-Botet M. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class la and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur J Immunol. 33:2744-2754, 2003.

Gumá M., Angulo A., Vilches C., Gomez-Lozano N., Malats N., López-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104: 3664-3671, 2004.

López-Botet M., Angulo A., Gumá M. NK cell receptors for MHC class I and related molecules in cytomegalovirus infection. Tissue Antigens 63: 195-203, 2004.

Dr  Carles Margarit Creixell

Cos J., Villalba T., Parra R., Gallardo D., Bilbao I., Margarit C., Massuet LL. FK506 in the maturation of dendritic cells. Haematologica, July 2002, vol. 87:679-687.

Cos J., Ocaña L., Quer J., Bilbao I., Esteban JI., Borràs FE., Tejeda M., Guardia J., Massuet Ll., Margarit C. FK506 down-regulated maturation of dendritic cells pulsed with a nonstructural protein (NS3) of hepatitis C virus. Transplantation (in revision).

Ocaña L., Cos J., Quer J., Bilbao I., Palou E., Parra R., Sauleda S., Esteban JI., Guàrdia J., Massuet Ll., Margarit C. Analysis of INF-?, TNF-a and dendritic cells to predict hepatitis C virus recurrence in liver transplant patients. (in revision).

Dr  Jaume Martorell Pons

Millan O., Brunet M., Martorell J., Garcia F., Vidal E., Rojo I., Plana M., Gallart T., Pumarola T., Miro JM., Gatell JM. Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Clin Pharmacokinet. 2005; 44(5):525-38.

Dr  Anna Meseguer Navarro

Dr  Emilio Itarte Fresquet

Dr  Francisco Javier Gómez Pérez

Teixidó N., Soler M., Rivera, N., Bernués J, Meseguer A. c/EBP-mediated role of TH in the developmental expression of the kidney androgen-regulated protein (KAP) gene in proximal convoluted tubules (in revision).

Tornavaca O., Llorens F., Itarte E,. Meseguer, A. In vivo phosphorylation of the kidney androgen-regulated protein (KAP) by casein kinase 2 (CK2). Functional characterization of CK2 mutated KAP domains (submitted).

Tornavaca O., Itarte E., Meseguer A. Subcellular location of the kidney androgen-regulated protein (KAP). Implications on cell cycle progression (in preparation).

Sarró E., Roher N, Tornavaca O., Meseguer A., Itarte E. Cyclosporine A interferes in the ERK1/2 i IkB( signaling pathways in renal proximal convoluted derived PCT cells. Effects of the kidney androgen-regulated protein (KAP) (submitted).

Puigmulé M., López-Hellin J., Meseguer A. Toxic effects of CsA in human and mouse proximal tubule derived cells. Proteomic analysis identifies molecular markers involved in toxicity (in preparation).

Dr  Pura Muñoz Cánoves

Parra M., Jard Mí., Koziczak M., Nagamine Y., Muñoz-Cánoves P. p53 phosphorylation at serine 15 is required for transcriptional induction of the plasminogen activator inhibitor- 1 (PAI-l) gene by the alkylating agent MNNG. J. Biol. Chem. 276: 36303-36310, 2001.

Suelves M., López-Alernany R., Lluís F., Aniorte G., Serrano E., Parra M., Carrneliet P., Muñoz-Cánoves P. Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood 99: 2835-2844, 2002.

López-Alemany R., Redondo JM., Nagamine Y., Muñoz-Cánoves P. Plasminogen Activator Inhibitor type-l Inhibits Insulin Signaling by competing with av¡33 integrin for Vitronectin Binding. Eur J Biochem.270: 814-821, 2003.

Vidal B., Ruiz V., Jardí M., Suelves M., Muñoz-Cánoves P. El activador del plasminógeno de tipo urokinasa y su receptor son necesarios para la adecuada implantación y neovascularización de injertos de piel. Hematologica 88: 289, 2003.

Tzarfaty-Majar V., López-Alemany R., Feinstein Y., Gomabau L., Goldshmidt O., Soriano E., Muñoz-Cánoves P., Klar A*. Plasmin-mediated release of the guidance molecule F-spondin from the extracellular matrix". (*both senior authors have equally contributed to this work; +both first authors have equally contributed to this work). J. Biol. Chem. 276: 28233-28241, 2001.

Lluís F., Roma J., Suelves M., Parra M., Aniorte G., Gallardo E., Illa I., Hughes SM., Carmeliet P., Roig M., Muñoz-Cánoves P. Urokinase-type plasminogen activator is required for skeletal muscle regeneration in vivo. Blood 97: 1703-1711, 2001.

López-Alemany R., Suelves M., Muñoz-Canoves P. Plasmin generation dependent on (-enolase-type plasminogen receptor is required for myogenesis. Thromb Haemost. 90: 724-733, 2003.

Dr  Estanis Navarro Gómez

Hueso M., Beltran V., Moreso F., Ciriero E., Fulladosa X., Grinyo JM., Serón D., Navarro E. Splicing alterations in human renal allografts: detection of a new splice variant of protein kinase Par1/Emk1 whose expression is associated with an increase of inflammation in protocol biopsies of transplanted patients. BBA-Molecular Basis of Disease 1689:58-65, 2004.

Hueso M., Alía P., Moreso F., Beltrán-Sastre V., Riera L., González C., Navarro MÁ., Grinyó JM., Navarro E., Serón D. Angiotensin converting enzyme genotype and chronic allograft nephropathy in protocol biopsies. J Am Soc Nephrol. 15:2229-36, 2004.

Beltran-Sastre V., Alluè M., Ciriero E., Martín J., Navarro E. Altered mRNA splicing and expression of the Par-1 polarity genes (MARK1, EMK1 and MARK3) in human colon tumors. Int. J Cancer, 2005 (in revision) .

Hueso M., Navarro E., Moreso F., Beltrán-Sastre Vi., Gil-Vernet S., Ventura F., Grinyó JM., Serón D. Genotype TT at codon 10 of Transforming Growth Factor-ß1 (TGF-ß1) gene, predisposes renal transplanted patients to subclinical rejection. J Am Soc Nephrol, 2005 (submitted).

Beltran-Sastre V., Hueso M., Navarro E. Cell polarity gene Par-1/EMK1 is required to maintain the structural integrity of the microtubule cytoskeleton and the polarization of T lymphoblasts, 2005 (in preparation).

Hueso M., Navarro E., Moreso F., Beltran-Sastre V., Ventura F., Grinyo J.M., Seron D Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels. Transplantation (2006) 81 (10):1463-1466.

Beltran-Sastre V., Hueso M., Navarro E. EMK1/hPar-1b determines front-rear polarity in T-lymphocytes Submitted (2007)

Hueso M., Navarro E., Moreso F, Beltrán-Sastre V., O'Valle F., García del Moral R., Grinyó J.M., Serón D. T Lymphocyte activation markers in subclinical renal allograft rejection  Manuscript in preparation (2007)

Hueso M., Mestre M., Moreso F., Beltrán-Sastre V, Bas J., Serón D, Grinyó J.M.,  Navarro E. Study of pretransplant lymphocyte subpopulations and activation markers as risk factors of acute rejection.  Manuscript in preparation (2007)

Dr  Federico Oppenheimer Salinas

Saurina A., Diekman F., Campos B., Piera C., Oppenheimer F., Campistol JM. Glomerular changes associated with the conversion from cyclosporine to sirolimus in patients with chronic allograft nephropathy. Nephrol Dial Transplant. 2005 (in press).

Dr  Mercè Pérez Riba

Genescà L., Aubareda A., Fuentes JJ., Estivill X., De La Luna S., Pérez Riba M. Phosphorylation of calcipressin 1 increases its ability to inhibit calcineurin and decreases calcipressin half-life. Biochem. J. 374:567-75 (2003).

Aubareda A., Mulero MC., Pérez Riba M. Functional characterizacterization of the calcipressin 1 motif responsible for calcineurin-mediated NFAT-dependent gene expression in human T cells  Cellular Signalling 18 (2006) 1430-1438.

Dr  Ricardo Enrique Pérez Tomás

Montaner B., Pérez- Tomás R. Prodigiosin induces caspase 9 and caspa se 8 activation and cytochrome c release in Jurkat cells. Annals of the New York Academv of Sciences. 2002; 973: 246-249.

Montaner B., Pérez- Tomás R. Activation of protein kinase C is required for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochemical Pharmacology, 2002; 63: 463-469.

Montaner B., Pérez- Tomás R. The cytotoxic prodigiosin induces phosphorylation of p38- MAPK but not of SAPK/JNK. Toxicology Letters, 2002; 129: 93-98.

Campàs C., Dalmau M., Montaner B., Barragán M., Bellosillo B., Colomer D., Pons G., Pérez-Tomás R., Gil J. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 2003, 17: 746-50.

Montaner B., Pérez-Tomás R. The prodigiosins: A new family of anticancer drugs. Current Cancer Drug Targets 2003, 3: 57-65.

Pérez-Tomás R., Montaner B., Llagostera E., Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochemical Pharmacology 2003, 66: 1447-52.

Soto-Cerrato V., Llagostera E., Montaner B., Scheffer G., Pérez-Tomás R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochemical Pharmacology 2004, 68:1345-52.

Llagostera E., Soto-Cerrato V., Joshi R., Montaner B., Gimenez-Bonafé P., Pérez-Tomás R. High cxytitoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. Anti-cancer Drugs 2005, 16(4):1-7.

Montaner B., Castillo-Avila W., Martinell M., Öllinger R., Aymami J., Giralt E., Pérez-Tomás R. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicological Sciences 2005.

Castillo-Avila W., Abal M., Robine S., Pérez-Tomás R. Non-apoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells  Life Sciences (in revision ).

Dr  José Luis Pomar Moya-Prats

Bañón E., Pomar-Moya JL., Climent F., Pérez de la Ossa P. Glycolytic enzime activities are decreased during acute rejection in transplanted rat hearts. Trasplantation Proceedings 2005 (in press).

Bañón, E., Khabiri E.; Climent, F., Pomar-Moya, J.L., Pérez de la Ossa, P. Serum creatine kinase levels correlates with heart rejection in an heterotopical heart tranplantation model in rats. Journal of Heart and Lung Transplantation.

Marín Soria J.L., Bañón E., Climent F., Pomar J.L., Pérez de la Ossa P. Cardiac troponin i serological levels after heart transplantation (in preparation).

Bañón E., Guerrero, M., Pomar-Moya J. L., Climent F., Pérez de la Ossa P. Metabolism changes during acute heart rejection (in preparation).

Dr  Ricardo Pujol Borrell

Dr  Anna Ribera Crusafont

Dr  Dolores Jaraquemada Pérez de Guzmán

Faner R., Casamitjana N., Colobran R., Ribera A., Pujol R., Palou E., Juan M. HLA-B27 genotyping by fluorescent resonance emission transfer (FRET) probes in real-time PCR. Human Immunology. 65, 826-838 (2004).

Casamitjana N., Faner R., Santamaria A., Colobran R., Ribera A., Pujol-Borrell R., Juan M., Palou E. Development of a new HLA-DRB Real-time PR typing method. Human Immunology, 66: 85-91 (2005).

Kolkowski EC., Fernández M, Pujol-Borrell R, Jaraquemada D. Human intestinal IELs in celiac disease: lower IL-10 synthesis and enhanced IL-2 production  Gastroenterology (sent ).

Kolkowski EC., Catálfamo M, Muxí L, Botello D, Morelli AE., Spies Ts, Groh V, Caillat-Zucman S, Pujol-Borrell Ri, Jaraquemada D. Clonal analysis of cell expansion in celiac disease defines functionally heterogeneous subsets and suggests new TCR epithelial ligands European Journal of Immunology (sent).

Dr  Francisco X. Real Arribas

Dr  Senén Vilaró Coma

Dr  Pierre Savatier

Soria B., Skoudy A., Martin F. From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus. Diabetologia 2001; 44:407-415.

Skoudy A., Rovira M., Savatier P., Martín F., Leon-Quinto T., Soria B., Real FX. Transforming growth factor beta, fibroblast growth factor, and retinoid signalling pathways promote exocrine gene expression in mouse embryonic stem cells. Biochem J 2004; 379:749-756.

Iglesias A., Murga M., Laresgoiti U., Skoudy A., Bernales I., Fullaondo A., Moreno B., Lloreta J., Field SJ., Real FX., Zubiaga A. Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 compound mutant mice reveals essential roles for these genes in pancreatic growth and differentiation. J Clin Invest 2004; 113:1398-1407.

Esni F., Ghosh B., Biankin AV., Lin JW., Albert MA., Yu X., MacDonald RJ., Civin CI., Real FX., Pack MA., Ball DW., Leach SD. Notch inhibits exocrine differentiation in developing mouse and zebrafish pancreas. Development 2004; 131:4213-4224.

León-Quinto T., Jones J., Skoudy A., Burcin M., Soria B. Directed differentiation of mouse embryonic stem cells towards insulin-producing cells. Diabetologia 2004; 47:1442-1451.

Rovira M., Jané-Valbuena J., Marchand M., Savatier P., Real FX., Skoudy A. Viral mediated co-expression of Pdx1 and p48 regulates pancreatic exocrine differentiation in ES cells Cloning Stem Cells 2007; (In press).

Rovira M., Merlos A., Real FX., Skoudy A. Molecular characterization of 266-6 mouse acinar tumor cells (in preparation).

Moriscot C., de Fraipont F., Richard MJ., Marchand M., Savatier P., Bosco D., Favrot M., Benhamou PY. Human Bone Marrow Mesenchymal Stem Cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells 2005, (en premsa).

Pagán R., Vilaró S., et al. (Ms. in preparation).

Pascual M., Abasolo I., Mingorance-LeMeur A., Martínez A., Del Rio J.A., Wright C.V.E., Real F.X., Soriano E. GABAergic cerebellar progenitors adopt an external granule cell-like phenotype in the absence of Ptf1a transcription factor expression. Proc Natl Acad Sci USA 2007; 104:5193-5198.

Dr  Antoni Rimola Castellà

Rimola A., Londoño MC., Guevara G., Bruguera M., Navasa M., Forns X., Garcia-Retortillo M., Garcia-Valdecasas JC., Rodes J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686-91.

Dr  Joan Roselló Catafau

Fernández L., Heredia N., Grande L., Gómez G., Rimola A., Marco A., Gelpí E., Roselló-Catafau J., Peralta C. Preconditioning Protects Liver and Lung Damage in Rat Liver Transplantation: Role of  Xanthine/Xanthine Oxidase. Hepatology 2002; 36:562-572.

Peralta C., Carlos Perales J., Bartrons R., Mitchell C., Gilgenkrantz H., Xaus C., Prats N., Fernández L., Gelpí E., Pané J., Roselló-Catafau J. The combination of ischemic preconditioning and liver Bc/2-overexpression is a suilable strategy to prevenl liver and lung damage arter hepatic ischemia-reperfusion. American Journal of Pathology 160, 2111-2121, 2002.

Dr  Antoni Sabaté Pes

Moreno C., Sabate A. Hemodynamic profile and tissular oxygenation during liver transplantation:influence of the arder in vascular clamp release. Liver Transpl. 2002 Dec;8 (12):1201-2.

Moreno C., Sabate A., Camprubi L., et al. Hemodynamic profile ans tisular oxygen during liver transplantation: Influence of the arder in hepatic vascular clamp release. Liver Intensive Care Group of Europe. Barcelona 2002.

Sabate A., Koo M., Dalmau A., Moreno C., et al. Perioperative factors associated to postoperative renal dysfunction in orthotopic liver transplantation. Eur J. Anaesthesiology 2003; A-594.

Farreres E., Sabate A., Figueras J., et al. Rocuronium valoration as an indicator of the hepatic function during the vascular clamp reperfusion of the hepatic graft: effect of changing the order vascular clamp release. Eur J. Anaesthesiology 2005, Vienn (in press).

Sabaté A., Koo M., Dalmau A., Moreno C. La monitorización anestesica. Tratado de Trasplante de Organos. Aran Ediciones. Madrid 2005 (in press).

Moreno C.,  Sabate A., Figueras J.,  Camprubí I.,  Dalmau A., Fabregat J., Koo M., Ramos E., Llado L.,  Rafecas A. Hemodynamic profile and tissular oxygenation in orthotopic liver transplantation: Influence of hepatic artery or portal vein revascularization of the graft Liver Transplantation 12: 1607-1614 (2006)

Dr  Miguel Santín Cerezales

Santin M., Shaw E., Mestre M., et al. Hepatitis C virus (HCV) coinfection delays immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 (HIV-1) disease. Journal of Clinical Immunology (in revision).

Shaw E., Robres P., Santin M. Influence of coinfection with HCV in long-term outcome of HIV-1-infected patients treated with antiretrovirals (in preparation).

Dr  Daniel Serón Micas

Serón D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 61: 727-733, 2002.

Serón D, Moreso F. Protocol biopsies and risk factors associated with chronic transplant nephropathy. Transplant Proc. 34: 331-332, 2002.

Fulladosa X, Moreso F, Narvaez JA, Hueso M, Caldés A, Gil-Vernet S, Castelao AM, Alsina J, Grinyó JM, Serón D. Total glomerular number in stable renal allografts. Transplant Proc. 34: 343-344, 2002.

Moreso F I Alperovich G, Fulladosa X, Gil-Vernet S, Ibernon M, Carrera M, Castelao AM, Hueso M, Grinyo JM, Serón D. Histologic findings in protocol biopsies perforrned in stable renal allografts under different immunosuppressive schedules. Transplant Proc. 35: 1666-8, 2003.

Fulladosa X, Moreso F, Narvaez JA, Grinyó JM, Serón D. Estimation of total glomerular number in stable renal transplant. J. Am. Soc. Nephro. 114:2662-8, 2003.

Fulladosa X, Moreso F, Torras J, Hueso M, Grinyó JM, Serón D. Structural and Functional Correlations in Stable Renal Allografts. Am. J. Kidney Dis 41,5: 1065-73, 2003.

Serón D. Protocol biopsies as predictors of chronic allograft nephropathy. Transplant Proc. 35: 2131-2, 2003.

Moreso F., Seron D., Carrera M., Gil-Vernet S., Cruzado JM., Hueso M., Fulladosa X., Ramos R., Ibernon M., Castelao AM., Grinyo JM. Baseline immnosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78 (7): 1064-1068.

Vallejos A., Alperovich G., Moreso F., Carrera M., Ibernon M., Fulladosa X., Goma M., Grinyo JM., Seron D. Correlation between histological findings in protocol renal allograft biopsies and arterial resistive index. Nephrol Dial Transplant 2005 (in press).

Serón D. Early diagnosis of chronic allograft nephropathy by means of protocol biopsies. Transplant Proc. 2004; 36: 763-764.

Moreso F., Lopez M., Vallejos A., Giordani C,. Riera L., Fulladosa X., Hueso M., Alsina J., Grinyo Jm., Seron D. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am. J. Transplant 2001; 1:82-88.

Alperovich G., Maldonado R., Moreso F., Fulladosa X., Grinyo Jm., Seron D. Glomerular enlargement assessed by paired donor and early protocol renal allograft biopsies. Am. J. Transplant 2004; 4: 1-5.

Lopes JA., Moreso F., Riera L., Carrera M., Ibernon M., Fulladosa X., Grinyó JM., Serón D. Evaluation of pre-implantation kidney biopsias; comparison of Banff criteria to morphometric approach. Kidney Int. 2005; 67: 1595-1600.

Hueso M., Beltran V., Moreso F., Ciriero E., Fulladosa X., Grinyó JM., Serón D., Navarro E. Splicing alterations in human renal allografts: detection of a new splice variant protein kinase Par1/Emk1 whose expression is associated with an increase of inflammation in protocol biopsies of transplant patients. Biochim Biophys Acta 2004; 1689: 58-65.

Hueso M., Alía P., Moreso F., Beltran-Sastre V., Riera L., González C., Navarro MA., Grinyó JM., Navarro E., Serón D. Angiotensin converting enzyme genotype and chronic allograft nephropathy in protocol biopsies. J. Am. Soc. Nephrol. 2004; 15: 2229-2236.

Hueso M., Bover J., Espinosa L., Moreso F., Serón D., Cañas C., Raulf F., Blanco A., Gil-Vernet S., Castelao Am., Grinyo Jm., Alsina J. TGF-?1 gene expression in protocol biopsies from patients with stable renal allograft function. Transplant Proc. 2001; 33: 342-344.

Hueso M., Navarro E., Moreso F., Beltrán-Sastre V, Ventura F., Grinyó JM., Serón D. Transforming growth factor-b1 genotype modulation of mRNA and plasma levels predispose to early lesions in renal transplant patients (submitted).

Dr  Joan Torras Ambros

Dr  Josep Maria Aran Perramon

Pluvinet R., Pétriz JM. Torras J., Herrero-Fresneda I., Cruzado JM., Grinyó JM., Aran JM. RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood. 104: 3642-3646 (2004).

Herrero-Fresneda I., Torras J., Cruzado JM., Condom E., Riera M., Lloberas N., Alsina J., Grinyó JM. Do alloreactivity and cold ischemia cause different elementary lesions on chronic allograft nephropathy?. Am J Pathol 162:127-137 (2003).

Herrero-Fresneda I., Torras J., Lloberas N., Vidal A., Cruzado JM., Grinyó JM. Reduction of post-ischemic renal inflammation: an effective strategy to attenuate chronic allograft nephropathy. Transplantattion 79: 165-173 (2005).

Dr  Antoni Trilla Garcia

Bertrán M.J.,  Prat A., Laia Bruni,  Roig E.,  Asenjo E.,  Trilla A. Análisis del coste del trasplante cardíaco en un hospital español .Med Clin (Barc). 2006;126(10):373-5

Dr  Víctor Vargas Blasco

Córdoba J., Ragué N., Flavia M., Vargas V., Jacas C., Alonso J., Rovira A. T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology 2003; 38:1026-1033.

Dr  Jordi Vives Puiggros

Mongay L., Plaza S., Vigorito E., Serra-Pagès C., Vives J. Association of the cell cycle regulatory proteins p45SKP2 and CksHs1. Functional effect on CDK2 complex formation and kinase activity. J Biol Chem. 276:25030-6, (2001).

Dr  F. Xavier Xiol Quingles

Lladó L., Figueras J.,  Ramos E.,  Membal R., Serrano T. ,  Torras J., Garcia-Gil  A.,  Gonzalez-Pinto I., Castellote J. , Baliellas C. , Fabregat J. ,  Rafecas A. and the THOSIN Study Group, Xiol X. Immunosuppression without steroids in liver transplantation is sale and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. Journal of Hepatology 44 (2006) 710-716. (p. 627-629 )

Dr  Jordi Yagüe Ribes

Font J., Garcia-Carrasco M., Ramos-Casals M., Aldea AI., Cervera R., Ingelmo M., Vives J., Yagüe J. The role of interleukin-10 promoter polymorphisms in the clinical expresion of primary Sjögren syndrome. Rheumathology 2002; 41:1025-1030.

Lozano F., Places L., Vila JM., Padilla O., Arman M., Gimferrrer I., Suarez B., Lopez de la Iglesia A., Miserachs N., Vives J. Identification of a novel single-nucleotide polymorphism (Val554Ile) and definition of eight common alleles for human IL4RA exon 11. Tissue Antigens 2001: 57; 216-220.

Aldea A., Casademont JI, Arostegui JI., Rius J., Masó M, Vives J., Yagüe J. I591T MEFV Mutation in a Spanish Kindred: Is It a Mild Mutation, a Benign Polymophism, or a Variant Influenced by Another Modifier?. Human Mutation 2002; 20:148-150.

Aganna E., Hammond L., Hawkins PN., Aldea A. Heterogeneity Among Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Phenotypes. Arthritis & Rheumatism Sept 2003; 48 (9): 2632-2644.

Aldea A., Campistol JM., Arostegui JI., Rius J., Maso M., Vives J., Yagüe J. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder?. American Journal of Medical Genetics A. 2004 Jan 1;124.(1):67-73.

Aldea A., Calafell F., Arostegui JI., Lao O., Rius J., Plaza S., Maso M., Vives J., Buades J., Yagüe J. The west side story: MEFV haplotype in Spanish FMF patients and controls, and evidence of high LD and a recombination hot-spot at the MEFV locus. Human Mutation 2004 Apr; 23 (4):399.

Arostegui JI., Aldea A., Modesto C., Rua MJ., Argüelles F., Gonzalez-Enseñat MA., Ramos E. Rius J., Plaza S., Vives J., Yagüe J. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis & Rheumatism. 2004 Dec; 50 (12): 4045-50.

Arostegui JI., Solis P., Aldea A., Cantero T., Rius J., Bahillo P., Plaza S., Vives J., Gomez S., Yagüe J. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. European Journal of Pediatrics. 2005 Jan;164 (1):13-6.

Ramos E., Arostegui JI., Campuzano S., Rius J., Bousoño C., Yagüe J. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology 2005.doi: 10.1093/rheumatology/keh652.